SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers sustained rally to a 52-week high and push through a long-watched round-number level are driving attention, with holders celebrating the recovery while skeptics question whether it can hold without a stronger company-specific catalyst. Traders are also watching the upcoming earnings report and pipeline developments for confirmation.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on reports that Trump ruled out an immediate U.S. strike on Iran, with many interpreting the news as a possible relief-driven futures bounce while others argue conflict and oil-supply risks are merely delayed. The debate is amplifying an already cautious, volatile outlook ahead of the Fed decision, major tech earnings and inflation data.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus stock-and-warrant offering has intensified concern about shareholder dilution and contributed to a steep selloff, alongside broader weakness in nuclear stocks. Traders are divided between viewing the pullback as a buying opportunity tied to domestic uranium-enrichment demand and worrying that valuation, expansion costs, and execution risks outweigh the long-term HALEU and DOE-contract potential.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

FDA clearance to expand Alpha Taus recurrent glioblastoma REGAIN trial and anticipated follow-up data are driving attention, alongside progress in its pancreatic cancer program. Traders are optimistic about the early GBM signal but acknowledge that it comes from a small cohort and await larger-data validation.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

Discussion is focused on the $17.05 million investor settlement: eligible shareholders are being reminded to file claims before the deadline, with a final approval hearing scheduled immediately afterward. Some traders view clearing the legal overhang as a positive, while others emphasize the settlements limited per-share recovery and historical allegations about Twists production and financial disclosures.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is under pressure as gold has weakened and rising rate expectations and yields weigh on precious metals and miners. Traders are divided between viewing the pullback and nearby support as a buying opportunity and expecting further losses if support gives way.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Volatile natural-gas futures are driving discussion, with traders weighing winter-weather demand and storage reports against mild-weather forecasts, strong production, and ample supply; pipeline and Freeport disruptions have also sparked sharp moves. Views are split on whether gas can sustain a rebound, while many warn that BOILs leveraged futures exposure and decay make it especially risky to hold.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Iran and broader Middle East tensions could disrupt oil supplies and shipping. Bulls see tight supply and continued geopolitical risk supporting the move, while bears argue the rally may be overextended and could reverse if tensions ease or a deal emerges.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Traders are focused on SQQQ as a leveraged hedge against the Nasdaq, citing tech weakness and concerns that heavy AI spending may not deliver adequate returns, alongside interest-rate and geopolitical risks. Some expect further downside in tech and favor SQQQ, while others caution that its daily leverage can erode value and that a Nasdaq rebound could reverse its gains.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung-cancer results for IMDELLTRA plus Imfinzi are drawing attention, with traders focused on the reported survival benefit and potential to expand the drugs role in earlier treatment. The community views the data as a meaningful pipeline catalyst, though some question how much it will change Amgens broader growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TSLA Eyes Best Week In 2 Months — Analyst Sees Physical Tech’s ‘Berkshire,’ But Bear Credits Court Ruling For Q3 Beat 

Equity

GLJ’s Gordon Johnson said tariff relief added $447 million to gross profit, masking an underlying earnings miss.

SPCX Stock Jumps Overnight: Musk Teases $1 Trillion Revenue By 2028 — Analyst Sees 95% Tesla Merger Odds In 2 Years 

Cathie Wood's ARK Investment Management analyst Brett Winton said Tesla shareholders looking beyond 2030 should favor a merger even without a premium.

Tesla Stock At $4,400? Cathie Wood's ARK Pins Hopes On Robotaxis, Sees SpaceX Merger In 5 Years

ARK says a Tesla-SpaceX merger could result in combined revenue of $3.8 trillion by 2031.

NIO Stock Climbs Overnight: EV Firm Outsells German Luxury Rivals In China Sales For First Time — CEO Hails Tesla’s Flying Roadster

CEO William Li praised Tesla’s flying Roadster, saying, “So impressive! This one we really don’t have.”

TSLA Stock Rises Overnight: Musk Bets Tesla’s Value On Optimus, Cybercab — Analyst Sees Flying ‘Halo Car’ Luring Buyers 

Morningstar sees the Roadster attracting buyers to Tesla’s broader lineup, despite forecasting fewer than 2,000 annual deliveries.

TSLA Stock Gets Some Thrust From ‘Flying’ Roadster Reveal — Munster Calls It ‘Engineering Flex’ With A Tesla-SpaceX Clue  

Tesla outlined Performance, Thrust and flight-capable Rocket versions, showcasing a 0-60 mph time of 0.81 seconds.

TSLA Stock Slips Overnight Ahead Of Roadster Event — Elon Musk Promises ‘Greatest Product Demo Of All Time’ 

Musk’s proposed SpaceX thruster package and past flying-car claims have raised expectations for the event.

TSLA Stock Climbs Overnight As Cybercab Eyes Dallas — Musk Recalls When Shorts Had Tesla In ‘Checkmate’

Tesla AI chief Ashok Elluswamy hinted that Cybercab rides could reach Dallas next.

TSLA Stock Heads For Weekly Win: Dan Ives Sees Over 30% Upside From AI, UBS Calls Setup ‘Tactically Favorable’ 

Ives sees software, robotaxis, robotics, and energy storage driving Tesla’s growth beyond vehicles.

TSLA Eyes Worst Week In 2 Months As Q3 Delivery Numbers Loom — But Munster Bets On A Beat As 'EV Winter' Thaws 

Musk also said Tesla cut AI5 RAM to 72 GB and AI6 to 144 GB to scale Optimus production.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Canaccord raised its target to $442, retaining 'Buy', and sees Tesla becoming the Berkshire Hathaway of physical tech.</li><li>Tesla reported over 1.7 million paid FSD customers, while New Street estimated annual recurring FSD revenue approaching $1 billion.</li><li>JPMorgan, Morgan Stanley and Mizuho raised targets, while SpaceX takeover potential prompted BNP Paribas to upgrade Tesla to 'Neutral'.</li></ul>Shares of Tesla, Inc. (TSLA) are on track for their best week in two months as Canaccord saw the makings of a Berkshire Hathaway of physical tech, while GLJ Research argued that tariff relief drove its third-quarter (Q3) earnings beat.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> fell 3% to $374.58 on Thursday but is still up 6% for the week, heading toward its strongest weekly gain since late August.&nbsp;Tesla reported adjusted earnings of $0.48 a share versus a $0.45 consensus, with revenue of $28.05 billion versus an expected $28.25 billion.&nbsp;<h2 class="st-heading-2">Canaccord Bets On Physical AI</h2>Canaccord raised its target to $442 from $410 and retained 'Buy', implying 17.8% upside. The firm sees Tesla potentially becoming the “Berkshire Hathaway of tomorrow’s physical technology,” using AI and connectivity to transform businesses on Earth and beyond.That vision spans autonomous transport, robotics, energy and semiconductor manufacturing. On the earnings call, CFO Vaibhav Taneja said: “I'd like to stress that what we are trying to do is literally take over every part of terrestrial transportation.”&nbsp; Tesla now has more than 1.7 million paid Full Self-Driving customers globally, half through subscriptions, Taneja said.New Street Research analyst Pierre Ferragu highlighted the recurring-revenue opportunity: “But then, of course, FSD generates more than $1,000 a year, so it makes a minimal impact on numbers in the quarter the car is sold. But over the lifetime of the car, it probably at least doubles the profit per car.” Ferragu estimated FSD was approaching $1 billion in annual recurring revenue. “Yeah, I think the numbers which you shared are correct,” Taneja replied.<h2 class="st-heading-2">GLJ Says Tariff Relief Masked An Earnings Miss</h2>On the other hand, GLJ Research’s Gordon Johnson focused on the quarter’s tariff benefit. “$TSLA’s Q3 beat came from a court ruling, not operations,” he&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/GordonJohnson19/status/2113292784597639536">said on X</a>, pointing to Note 11 of Tesla’s quarterly filing.Tesla’s filing shows the Supreme Court tariff ruling unlocked $786 million in cost reductions, including 526 million in energy and $260 million in automotive, offset by a $339 million revenue reduction for customer refunds.Johnson put the net gross-profit boost at $447 million, or 62% of operating income. Without it, he calculated gross margin at 17.8%, down from 19.6%, and operating margin at 1%, versus 2.6% reported and 1.4% in the previous quarter.His recalculations turned earnings beats into misses: “GAAP EPS: $0.22 → $0.12 vs $0.20 est.” and “Non-GAAP EPS: $0.48 → $0.38 vs $0.44 est.” He used a $0.44 adjusted consensus, versus the $0.45 figure.&nbsp;Johnson estimated energy gross margin at about 23.8% excluding refunds, versus 33.1% reported, with the adjusted figure still benefiting from a vendor warranty adjustment. He put automotive margin excluding credits at 16.8%, versus 18.1% reported, and cited 39% operating-expense growth. “$TSLA's gross profit is not keeping pace with spending,” he said.Taneja also acknowledged on the call that tariff refunds and warranty adjustments primarily drove the sequential energy-margin improvement.<h2 class="st-heading-2">Analysts Lift Targets, Flag Spending Risks</h2>JPMorgan raised its target to $430 from $415, retaining 'Neutral' and implying 15% upside. It welcomed stronger margins and autonomy progress but flagged spending, with SpaceX speculation supporting shares. Morgan Stanley lifted its target to $410 from $400, keeping 'Equal Weight' and implying 9.2% upside, on Robotaxi, FSD and improving fundamentals.Mizuho raised its target to $460 from $450, retaining 'Outperform' and implying 23% upside. Cantor Fitzgerald maintained 'Overweight' and $485, implying 29% upside, citing autonomy and robotics opportunities despite uncertain commercialization timelines.SpaceX takeover potential drove BNP Paribas’s upgrade to 'Neutral' from 'Underperform' and target increase to $420 from $266, implying 11.9% upside, despite AI execution and cash-burn concerns.Morningstar maintained a $475 standalone fair value estimate, implying 26.6% upside, and saw merger synergies across energy, AI and connectivity. “We think valuation (specifically, the merger ratio for each company) is likely a sticking point in negotiations,” it said.<h2 class="st-heading-2">How Do Retail Traders Feel About TSLA?</h2>On Stocktwits, retail sentiment for TSLA flipped to ‘bearish’ from ‘bullish’ levels a day ago amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tsla_ss_d7a8d3485f.png" alt="tsla ss.png" width="638" height="335"><figcaption>TSLA sentiment and message volume as of October 23 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BuffMan101/message/667194070">said</a>, “$TSLA is an super expensive stock why would $SPCX want to merge and dilute shareholders? Why would Musk want to??? I think the obvious reason is clear…Musk is the best financial engineer/manipulator in the history of mankind!”<stembedurl>https://stocktwits.com/BuffMan101/message/667194070</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/j_bauer5/message/667161952">said</a>, “$TSLA for this to be bullish needs to push past 378.5 and retest to the upside”<stembedurl>https://stocktwits.com/j_bauer5/message/667161952</stembedurl>So far this year, Tesla's stock has lagged its "Magnificent Seven" peers, making it the group's worst performer, down about 17%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-retail-upside-spacex-site-push-fcc-adviser-global-satellite-power-race/cZxy5NTRBDx">ASTS Slips Overnight: Retail Sees Upside In SpaceX’s 80,000-Site Push — FCC Adviser Sees Global Satellite Power Race&nbsp;</a>

In this photo illustration, the stock market information of Tesla Inc displayed on a smartphone while the logo of Tesla Inc seen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

TSLA Eyes Best Week In 2 Months — Analyst Sees Physical Tech’s ‘Berkshire,’ But Bear Credits Court Ruling For Q3 Beat

Leverage Shares 2x Long SPCX Daily ETF

Defiance Daily 2X Space ETF

Tradr 2X Long SpaceX Daily ETF

SpaceX

Direxion Daily TSLA Bull 2X Shares

Tradr 2X Short TSLA Daily ETF

T-REX 2X Long Tesla Daily Target ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

TSLQ News